| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44029819 | HTLV-1 | ENSG00000144908.14 | protein_coding | ALDH1L1 | No | No | 10840 | O75891 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ALDH1L1 |
|---|---|
| DrugBank ID | DB00116 |
| Drug Name | Tetrahydrofolic acid |
| Target ID | BE0000933 |
| UniProt ID | O75891 |
| Regulation Type | cofactor |
| PubMed IDs | 10395731; 10585460; 11320079; 16627483; 16712799 |
| Citations | Fu TF, Maras B, Barra D, Schirch V: A noncatalytic tetrahydrofolate tight binding site is on the small domain of 10-formyltetrahydrofolate dehydrogenase. Arch Biochem Biophys. 1999 Jul 15;367(2):161-6.@@Krupenko SA, Wagner C: Aspartate 142 is involved in both hydrolase and dehydrogenase catalytic centers of 10-formyltetrahydrofolate dehydrogenase. J Biol Chem. 1999 Dec 10;274(50):35777-84.@@Krupenko SA, Vlasov AP, Wagner C: On the role of conserved histidine 106 in 10-formyltetrahydrofolate dehydrogenase catalysis: connection between hydrolase and dehydrogenase mechanisms. J Biol Chem. 2001 Jun 29;276(26):24030-7. Epub 2001 Apr 24.@@Anguera MC, Field MS, Perry C, Ghandour H, Chiang EP, Selhub J, Shane B, Stover PJ: Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. J Biol Chem. 2006 Jul 7;281(27):18335-42. Epub 2006 Apr 20.@@Oleinik NV, Krupenko NI, Reuland SN, Krupenko SA: Leucovorin-induced resistance against FDH growth suppressor effects occurs through DHFR up-regulation. Biochem Pharmacol. 2006 Jul 14;72(2):256-66. Epub 2006 Apr 25. |
| Groups | Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2)N1 |
| Pathways | Histidinemia; Lesch-Nyhan Syndrome (LNS); Molybdenum Cofactor Deficiency; Azathioprine Action Pathway; AICA-Ribosiduria; Purine Nucleoside Phosphorylase Deficiency; Methionine Adenosyltransferase Deficiency; Folate Malabsorption, Hereditary; Adenine Phosphoribosyltransferase Deficiency (APRT); Thioguanine Action Pathway; Mercaptopurine Action Pathway; Non-Ketotic Hyperglycinemia; Methotrexate Action Pathway; Betaine Metabolism; S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Glycine and Serine Metabolism; Adenosine Deaminase Deficiency; Xanthinuria Type II; Methionine Metabolism; Dihydropyrimidine Dehydrogenase Deficiency (DHPD); Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Folate Metabolism; Sarcosine Oncometabolite Pathway; Sarcosinemia; Methylenetetrahydrofolate Reductase Deficiency (MTHFRD); Purine Metabolism; Gout or Kelley-Seegmiller Syndrome; Adenylosuccinate Lyase Deficiency; Ammonia Recycling |
| PharmGKB | PA164745110 |
| ChEMBL | CHEMBL2021342 |
